BioCentury | Sep 8, 2014
Product Development

Betting big on hearts

Though saturation by cheap generics and a high-profile failure of another compound led some companies to exit the heart failure space, results from the PARADIGM-HF trial suggest Novartis AG made the right call by doubling...
BioCentury | Apr 28, 2014
Strategy

Bigger is better

Novartis AG is showing every sign of continuing to think big. Ridding itself of low-performing businesses while doubling down on cancer will help the pharma increase its operating income in the short term and plug...
BC Week In Review | Dec 24, 2012
Company News

Vivacta, Novartis deal

Novartis acquired diagnostic company Vivacta for $90 million. Vivacta could not be reached for comment while Novartis said the deal provides it with access to Vivacta's platform to develop point-of-care diagnostic tests to improve therapeutic...
BC Week In Review | Feb 27, 2012
Company News

Atlas Genetics board of directors update

Atlas Genetics Ltd. , Bristol, U.K.   Business: Diagnostic   Appointed: Neil Butler as chairman, formerly CEO of Vivacta Ltd. ; he succeeds Mike Saunders, who remains a director  ...
BC Week In Review | Nov 15, 2010
Financial News

Vivacta completes venture financing

Vivacta Ltd. , Sittingbourne, U.K.   Business: Diagnostic   Date completed: 11/10/10   Type: Venture financing   Raised: £4 million ($6.4 million)   Investors: HBM BioVentures; IDInvest Partners; Spark Ventures; Viking  ...
BC Week In Review | Aug 30, 2010
Company News

Vivacta management update

Vivacta Ltd. , Sittingbourne, U.K.   Business: Diagnostic   Hired: Oliver Boucher as CBO and a director, formerly CBO of Sigmoid Pharma Ltd.   Transitioned: Tim Carter to CEO from CSO; he replaces Neil Butler, who...
Items per page:
1 - 6 of 6
BioCentury | Sep 8, 2014
Product Development

Betting big on hearts

Though saturation by cheap generics and a high-profile failure of another compound led some companies to exit the heart failure space, results from the PARADIGM-HF trial suggest Novartis AG made the right call by doubling...
BioCentury | Apr 28, 2014
Strategy

Bigger is better

Novartis AG is showing every sign of continuing to think big. Ridding itself of low-performing businesses while doubling down on cancer will help the pharma increase its operating income in the short term and plug...
BC Week In Review | Dec 24, 2012
Company News

Vivacta, Novartis deal

Novartis acquired diagnostic company Vivacta for $90 million. Vivacta could not be reached for comment while Novartis said the deal provides it with access to Vivacta's platform to develop point-of-care diagnostic tests to improve therapeutic...
BC Week In Review | Feb 27, 2012
Company News

Atlas Genetics board of directors update

Atlas Genetics Ltd. , Bristol, U.K.   Business: Diagnostic   Appointed: Neil Butler as chairman, formerly CEO of Vivacta Ltd. ; he succeeds Mike Saunders, who remains a director  ...
BC Week In Review | Nov 15, 2010
Financial News

Vivacta completes venture financing

Vivacta Ltd. , Sittingbourne, U.K.   Business: Diagnostic   Date completed: 11/10/10   Type: Venture financing   Raised: £4 million ($6.4 million)   Investors: HBM BioVentures; IDInvest Partners; Spark Ventures; Viking  ...
BC Week In Review | Aug 30, 2010
Company News

Vivacta management update

Vivacta Ltd. , Sittingbourne, U.K.   Business: Diagnostic   Hired: Oliver Boucher as CBO and a director, formerly CBO of Sigmoid Pharma Ltd.   Transitioned: Tim Carter to CEO from CSO; he replaces Neil Butler, who...
Items per page:
1 - 6 of 6